A randomized, controlled, open-label, 48-week study of continuing successfully suppressive treatment in HIV-1 infected adults with first-line twice-daily zidovudine and lamivudine-based regimens versus pro-actively replacing of zidovudine and lamivudine by once-daily emtricitabine and tenofovir disoproxil fumarate to prevent progression of or reverse peripheral lipoatrophy

Trial Profile

A randomized, controlled, open-label, 48-week study of continuing successfully suppressive treatment in HIV-1 infected adults with first-line twice-daily zidovudine and lamivudine-based regimens versus pro-actively replacing of zidovudine and lamivudine by once-daily emtricitabine and tenofovir disoproxil fumarate to prevent progression of or reverse peripheral lipoatrophy

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2013

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms PREPARE
  • Most Recent Events

    • 08 Mar 2012 Results from a substudy assessing the effects of treatment on bone metabolism and bone mineral density presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
    • 10 Jun 2010 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top